Enovis Co. (NYSE:ENOV) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Enovis Co. (NYSE:ENOV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $65.86.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. River Road Asset Management LLC acquired a new position in shares of Enovis in the 3rd quarter valued at $51,341,000. Raymond James Financial Inc. acquired a new position in shares of Enovis in the fourth quarter valued at about $16,407,000. Royce & Associates LP increased its holdings in shares of Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock valued at $103,479,000 after purchasing an additional 346,317 shares during the period. Diamond Hill Capital Management Inc. raised its stake in shares of Enovis by 7.8% in the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock worth $129,352,000 after purchasing an additional 218,660 shares during the last quarter. Finally, Artemis Investment Management LLP lifted its holdings in shares of Enovis by 35.4% during the fourth quarter. Artemis Investment Management LLP now owns 665,868 shares of the company's stock worth $29,218,000 after purchasing an additional 174,116 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Trading Down 5.0 %

Shares of NYSE:ENOV traded down $2.34 during trading hours on Monday, hitting $44.77. 890,827 shares of the company's stock traded hands, compared to its average volume of 1,145,443. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a fifty day moving average price of $45.98 and a 200-day moving average price of $44.51. Enovis has a 1 year low of $38.27 and a 1 year high of $65.03. The firm has a market capitalization of $2.55 billion, a P/E ratio of -20.44 and a beta of 1.94.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to analysts' expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm's quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 EPS. Equities analysts expect that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.